Discover NEXThaler®: Designed with your patients in mind
Watch this short animation to see how Trimbow® (beclometasone/ formoterol/ glycopyrronium) NEXThaler® delivers triple therapy in a breath-actuated dry powder inhaler (DPI), combining clinical efficacy with patient-friendly features.1-4
Talk to us
Request a call or meeting with your local Chiesi representative at a time which suits you.
Order training inhalers
Support your patients with their inhaler technique by ordering placebo training inhalers directly from Chiesi.
Sign up for updates
Want to hear more from Chiesi? Opt-in to receive updates on Chiesi Air products and services.
References
-
- Beeh KM, et al. Int J Chron Obstruct Pulmon Dis. 2021; 16: 79–89.
- Rust S, et al. What inhaler device features are most valued by patients? Presented at PCRS Congress 2025, Telford, U.K., September 18-20, 2025.
- Varacca G, et al. Eur J Pharm Sci. 2023; 183: 106385.
- Voshaar T, et al. J Aerosol Med Pulm Drug Deliv. 2014; 27(5): 363–370.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.